- Home
- KOSS vs MGX Comparison
KOSS vs MGX Comparison
Compare KOSS & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- MGX
- Stock Information
- Founded
- KOSS 1953
- MGX 2018
- Country
- KOSS United States
- MGX United States
- Employees
- KOSS N/A
- MGX N/A
- Industry
- KOSS Consumer Electronics/Appliances
- MGX
- Sector
- KOSS Consumer Staples
- MGX
- Exchange
- KOSS Nasdaq
- MGX NYSE
- Market Cap
- KOSS 59.3M
- MGX 62.1M
- IPO Year
- KOSS N/A
- MGX 2024
- Fundamental
- Price
- KOSS $5.14
- MGX $1.45
- Analyst Decision
- KOSS
- MGX Strong Buy
- Analyst Count
- KOSS 0
- MGX 4
- Target Price
- KOSS N/A
- MGX $13.00
- AVG Volume (30 Days)
- KOSS 113.4K
- MGX 412.1K
- Earning Date
- KOSS 05-08-2025
- MGX 08-13-2025
- Dividend Yield
- KOSS N/A
- MGX N/A
- EPS Growth
- KOSS N/A
- MGX N/A
- EPS
- KOSS N/A
- MGX N/A
- Revenue
- KOSS $12,433,361.00
- MGX $45,263,000.00
- Revenue This Year
- KOSS N/A
- MGX N/A
- Revenue Next Year
- KOSS N/A
- MGX $11.75
- P/E Ratio
- KOSS N/A
- MGX N/A
- Revenue Growth
- KOSS N/A
- MGX N/A
- 52 Week Low
- KOSS $3.81
- MGX $1.23
- 52 Week High
- KOSS $18.73
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- KOSS 46.52
- MGX 40.18
- Support Level
- KOSS $4.63
- MGX $1.41
- Resistance Level
- KOSS $6.16
- MGX $1.59
- Average True Range (ATR)
- KOSS 0.39
- MGX 0.13
- MACD
- KOSS -0.13
- MGX -0.02
- Stochastic Oscillator
- KOSS 33.33
- MGX 11.32
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.